Treatment of severe complications of Fontan circulation with Endothelin1 dual (A and B) receptor antagonist Bosentan

被引：0
|
作者：
Milanesi, O. [1 ]
Scarabeo, V. [2 ]
Maschietto, N. [1 ]
Biffanti, R. [1 ]
Patuelli, G. [3 ]
机构：
[1] Dolo Hosp, Dept Cardiol, Dolo, Ve, Italy
[2] P Cosma Hosp, Dept Cardiol, Camposampiero, Pd, Italy
[3] Actel Pharmaceut Italy, Dept Med, Imola, Bo, Italy
来源：
EUROPEAN HEART JOURNAL | 2009年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：808 / 808
页数：1
相关论文
共 50 条
  • [31] Beneficial hemodynamic effects of bosentan, an ET(A) and ET(B) receptor antagonist of endothelin in portal hypertension.
    Lebrec, D
    Cailmail, S
    Moreau, R
    Gadano, A
    Clozel, M
    HEPATOLOGY, 1996, 24 (04) : 759 - 759
  • [32] A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage TV metastatic melanoma
    Kefford, R
    Beith, J
    Van Hazel, GA
    Millward, M
    Trotter, J
    Wyld, D
    Kusic, R
    Coward, J
    Shreeniwas, R
    Morganti, A
    ANNALS OF ONCOLOGY, 2005, 16 : 312 - 312
  • [33] A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma
    Richard Kefford
    Jane McNeil Beith
    Guy Arthur Van Hazel
    Michael Millward
    James Marshall Trotter
    David Keith Wyld
    Rada Kusic
    Revati Shreeniwas
    Adele Morganti
    Andrea Ballmer
    Eleonor Segal
    Oliver Nayler
    Martine Clozel
    Investigational New Drugs, 2007, 25 : 247 - 252
  • [34] Contribution of endothelin-1 to myocardial injury in a murine model of myocarditis - Acute effects of bosentan, an endothelin receptor antagonist
    Ono, K
    Matsumori, A
    Shioi, T
    Furukawa, Y
    Sasayama, S
    CIRCULATION, 1999, 100 (17) : 1823 - 1829
  • [35] Endothelin A and B receptor antagonist bosentan reduces postischemic myocardial injury in the rat: critical timing of administration
    Xia, ZY
    Kuo, KH
    McNeill, JH
    Ansley, DM
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2005, 83 (03) : 259 - 266
  • [36] A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma
    Kefford, Richard
    Beith, Jane McNeil
    Van Hazel, Guy Arthur
    Millward, Michael
    Trotter, James Marshall
    Wyld, David Keith
    Kusic, Rada
    Shreeniwas, Revati
    Morganti, Adele
    Ballmer, Andrea
    Segal, Eleonor
    Nayler, Oliver
    Clozel, Martine
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (03) : 247 - 252
  • [37] Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension - A 1-year follow-up study
    Sitbon, O
    Basesch, DB
    Channick, RN
    Frost, A
    Robbins, IM
    Simonneau, G
    Tapson, VF
    Rubin, LJ
    CHEST, 2003, 124 (01) : 247 - 254
  • [38] Longterm Treatment with Endothelin Receptor Antagonist Bosentan and Iloprost Improves Fingertip Blood Perfusion in Systemic Sclerosis
    Cutolo, Maurizio
    Ruaro, Barbara
    Pizzorni, Carmen
    Ravera, Francesca
    Smith, Vanessa
    Zampogna, Giuseppe
    Paolino, Sabrina
    Seriolo, Bruno
    Cimmino, Marco
    Sulli, Alberto
    JOURNAL OF RHEUMATOLOGY, 2014, 41 (05) : 881 - 886
  • [39] Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan
    Humbert, M
    Cabane, J
    RHEUMATOLOGY, 2003, 42 (01) : 191 - 193
  • [40] Treatment of pulmonary arterial hypertension with macitentan, dual endothelin receptor antagonist
    Bichara, Valentina M.
    Bevacqua, Raul J.
    INSUFICIENCIA CARDIACA, 2019, 14 (03) : 119 - 128
12345